Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy

Lung Cancer Clinical Trial

Official title:

A Clincal Trial of Apatinib Mesylate and Etoposide(VP-16) as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03135977
• Other study ID #: Ahead-SL-20170220
• Status: Recruiting
• Phase: Phase 2
• First received: April 27, 2017
• Last updated: December 5, 2017
• Start date: March 1, 2017
• Est. completion date: December 2018

Study information

• Verified date: December 2017
• Source: Sichuan Cancer Hospital and Research Institute
• Contact: Xionghong Cai, Doctor
• Phone: 8618036672884
• Email: xionghong_cai[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and etoposide(CE) has been given, patients with extensive small cell lung cancer(ED-SCLC) still relapse and the 2-year survival is extremely low. There is no standard maintenance treatment recommendation for ED-SCLC patients after the first-line therapy.Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in small cell lung cancer is still lack of evidence-based medicine,so this clinical trial is designed to investigate the efficacy and safety of apatinib combine with etoposide as maintenance therapy in ED-SCLC patients after first-line chemotherapy in our center.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologic or cytologic diagnosis of extensive-stagesmall cell lung caner(SCLC) ,after first-line therapy

• Performance status of 0~2 on the ECOG criteria

• Expected survival is above three months

• Adequate hematologic (neutrophil count>=1.5×109/L, hemoglobin>=80g/L, platelets>=80×109/L), hepatic function (aspartate transaminase (AST) & alanine transaminase(ALT) =<upper normal limit(UNL) x2, bilirubin level =< UNL x 1.5)

• Patients have the ability to understand and voluntarily sign the informed consent, and allow adequate follow-up.

Exclusion Criteria:

• suffered from other tumor within 5 years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder epithelial tumor).

• Difficulties in taking pills (inability to swallow tablets,GI tract resection, chronic bacillary diarrhea and intestinal obstruction).

• Bleeding tendency or coagulation disorders.

• Uncontrolled hypertension (systolic pressure>150 mmHg , or diastolic pressure> 90 mmHg).

• Urine protein=++, or urine protein in 24 hours=2.0g.

• severe uncured wounds, ulcers or fracture.

• Pregnant or breast-feeding.

• Patients with epilepsy who need to take medicine (such as steroids or anti epilepsy agents).

• The researcher believe that the Patient is not suitable to participate in the study.

Related Conditions & MeSH terms

• Extensive-stage Small Cell Lung Cancer
• Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Drug:
• Apatinib, Etoposide
Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .

Locations

Country	Name	City	State
China	Sicchuan cancer hospital	Chendu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Sichuan Cancer Hospital and Research Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	The first day of treatment to the date that disease progression is reported	6 months
Secondary	Overall survival	the first day of treatment to death or last survival confirm date	up to 24 months
Secondary	Duration of Response	Duration of response is defined as time from the date of the first observed hematologic improvement to the date of the first subsequent documented disease progression or relapse	up to 24 months
Secondary	Tumor response rate	The ratio between the number of responders and number of patients assessable for tumor response.	Time Frame: 3 month
Secondary	Quality of Life (QoL) questionnaire	in cancer patients and survivors with dermatologic conditions. This is a nontherapeutic and nondiagnostic protocol to obtain quality of life assessments from cancer patients and survivors who have dermatologic conditions, whether related to cancer therapies, or directly related to the primary cancer diagnosis. Data will be collected by using one or more dermatology-specific QoL instruments based on the underlying skin condition/s.	up to 24 months